Основная статистика
| LEI | 549300U41AUUVOAAOB37 |
| CIK | 889131 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Roche Holding AG - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| March 21, 2023 |
Exhibit (a) TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 2 (d) Beneficial Owner 2 (e) Commission 2 (f) Custodian 2 (g) Deliver, execute, issue et al. 2 (h) Delivery Order 2 (i) Deposited Securities 2 (j) Direct Registration System 3 (k) Holder 3 (l) Securities Act of 1933 3 (m) Securities Exchange Act of |
|
| March 21, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 21, 2023. As filed with the U.S. Securities and Exchange Commission on March 21, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOR DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS ROCHE HOLDING LTD (Exact name of issuer of deposited securities as specified in its charter) N/A (Tr |
|
| March 21, 2023 |
Exhibit (d) March 21, 2023 Norton Rose Fulbright US LLP 1301 Avenue of the Americas New York, New York 10019-6022 JPMorgan Chase Bank, N. |
|
| March 20, 2019 |
SENS / Senseonics Holdings, Inc. / ROCHE HOLDING LTD - FORM SC 13D/A Activist Investment SC 13D/A 1 e4388sch13da.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Senseonics Holdings, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 81727U105 (CUSIP Number) David G. Dargatis, Esquire McGuireWoods LLP 1750 Tysons Boulevard Suite 1800 Tysons |
|
| July 31, 2018 |
FMI / Foundation Medicine, Inc. / ROCHE HOLDING LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 4) Under the Securities Exchange Act of 1934 Foundation Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 350456100 (CUSIP Number) Beat Kraehenmann Roche Holding Ltd Grenzacherstrasse 124 CH-4070 Basel, Switzerland Telephone: +41-61-688-1111 ( |
|
| June 19, 2018 |
Exhibit 99.1 AGREEMENT AND PLAN OF MERGER dated as of June 18, 2018 among FOUNDATION MEDICINE, INC., ROCHE HOLDINGS, INC. and 062018 Merger Subsidiary, Inc. TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 10 Article 2 The Offer Section 2.01. The Offer 10 Section 2.02. Company Action 12 Article 3 The Merger Sect |
|
| June 19, 2018 |
FMI / Foundation Medicine, Inc. / ROCHE HOLDING LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 3) Under the Securities Exchange Act of 1934 Foundation Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 350456100 (CUSIP Number) Beat Kraehenmann Roche Holding Ltd Grenzacherstrasse 124 CH-4070 Basel, Switzerland Telephone: +41-61-688-1111 ( |
|
| January 2, 2018 |
EX-99.1 Exhibit 99.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AMONG ROCHE HOLDINGS, INC., ABINGDON ACQUISITION CORP. and IGNYTA, INC. Dated as of December 21, 2017 ARTICLE I THE OFFER 5 Section 1.01. The Offer 5 Section 1.02. Company Actions 7 Section 1.03. Merger of Purchaser into the Company 8 Section 1.04. Closing 8 Section 1.05. Effective Time 8 Section 1.06. Effects of the Merger 9 Sect |
|
| January 2, 2018 |
RXDX / Ignyta, Inc. / ROCHE HOLDING LTD - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Ignyta, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 451731103 (CUSIP Number) Beat Kraehenmann Roche Holding Ltd Grenzacherstrasse 124 CH-4070 Basel, Switzerland Telephone: +41-61-688-1111 (Name, Ad |
|
| January 2, 2018 |
EX-99.1 Exhibit 99.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AMONG ROCHE HOLDINGS, INC., ABINGDON ACQUISITION CORP. and IGNYTA, INC. Dated as of December 21, 2017 ARTICLE I THE OFFER 5 Section 1.01. The Offer 5 Section 1.02. Company Actions 7 Section 1.03. Merger of Purchaser into the Company 8 Section 1.04. Closing 8 Section 1.05. Effective Time 8 Section 1.06. Effects of the Merger 9 Sect |
|
| January 2, 2018 |
EX-99.2 Exhibit 99.2 Execution Version Confidential TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of December 21, 2017, is by and among Roche Holdings, Inc., a Delaware corporation (“Parent”), Abingdon Acquisition Corp., a Delaware corporation (“Purchaser”) and an indirect wholly owned subsidiary of Parent, and each of the Persons set forth on Schedule |
|
| June 9, 2017 |
EX-1.1 Exhibit 1.1 Joint Filing Agreement The undersigned hereby agree that this Schedule 13D (the “Schedule 13D”) with respect to the common stock of Senseonics Holdings, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 193 |
|
| June 9, 2017 |
SENSEONICS HOLDINGS, INC. WARRANT TO PURCHASE COMMON STOCK No. PSW- December 7, 2015 Void After EX-1.2 3 d402735dex12.htm EX-1.2 Exhibit 1.2 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND MAY NOT BE OFFERED, SOLD, MORTGAGED OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECT |
|
| June 9, 2017 |
SENSEONICS HOLDINGS, INC. WARRANT TO PURCHASE COMMON STOCK No. PSW- December 7, 2015 Void After EX-1.2 3 d402735dex12.htm EX-1.2 Exhibit 1.2 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND MAY NOT BE OFFERED, SOLD, MORTGAGED OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECT |
|
| June 9, 2017 |
EX-1.1 Exhibit 1.1 Joint Filing Agreement The undersigned hereby agree that this Schedule 13D (the “Schedule 13D”) with respect to the common stock of Senseonics Holdings, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 193 |
|
| June 9, 2017 |
SENSEONICS HOLDINGS, INC. WARRANT TO PURCHASE COMMON STOCK No. PSW- December 7, 2015 Void After EX-1.2 3 d402735dex12.htm EX-1.2 Exhibit 1.2 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND MAY NOT BE OFFERED, SOLD, MORTGAGED OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECT |
|
| June 9, 2017 |
EX-1.1 Exhibit 1.1 Joint Filing Agreement The undersigned hereby agree that this Schedule 13D (the “Schedule 13D”) with respect to the common stock of Senseonics Holdings, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 193 |
|
| June 9, 2017 |
SENS / Senseonics Holdings, Inc. / ROCHE HOLDING LTD - SC 13D Activist Investment SC 13D 1 d402735dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Senseonics Holdings, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 81727U105 (CUSIP Number) David G. Dargatis, Esquire McGuireWoods LLP 1750 Tysons Boulevard Suite 1800 Tysons, VA 22102-4215 (703) 712- |
|
| June 7, 2017 |
POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents, that the undersigned hereby constitutes and appoints each of Darren K. |
|
| June 7, 2017 |
POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents, that the undersigned hereby constitutes and appoints each of Darren K. |
|
| June 7, 2017 |
POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents, that the undersigned hereby constitutes and appoints each of Darren K. |
|
| February 7, 2017 |
SENS / Senseonics Holdings, Inc. / ROCHE HOLDING LTD - SC 13G Passive Investment SC 13G 1 a17-39721sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SENSEONICS HOLDINGS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 81727U105 (CUSIP Number) DECEMBER 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 7, 2017 |
AVXS / AveXis, Inc. / ROCHE HOLDING LTD - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AVEXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 05366U100 (CUSIP Number) DECEMBER 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d |
|
| November 17, 2016 |
Unassociated Document Certification under Rule 466 The depositary, JPMorgan Chase Bank, N. |
|
| November 17, 2016 |
Unassociated Document J.P. Morgan J.P. Morgan AMENDMENT NO. 1, dated as of November , 2016 (the "Amendment"), to the Third Amended and Restated Deposit Agreement dated as of February 27, 2014 (the "Deposit Agreement") among Roche Holding Ltd (the "Company"), incorporated under the laws of Switzerland, JPMorgan Chase Bank, N.A., as depositary (the "Depositary"), and all holders from time to time of |
|
| November 17, 2016 |
Unassociated Document J.P. Morgan J.P. Morgan AMENDMENT NO. 1, dated as of November , 2016 (the "Amendment"), to the Third Amended and Restated Deposit Agreement dated as of February 27, 2014 (the "Deposit Agreement") among Roche Holding Ltd (the "Company"), incorporated under the laws of Switzerland, JPMorgan Chase Bank, N.A., as depositary (the "Depositary"), and all holders from time to time of |
|
| November 17, 2016 |
Unassociated Document Certification under Rule 466 The depositary, JPMorgan Chase Bank, N. |
|
| November 17, 2016 |
Unassociated Document Certification under Rule 466 The depositary, JPMorgan Chase Bank, N. |
|
| November 17, 2016 |
Unassociated Document Certification under Rule 466 The depositary, JPMorgan Chase Bank, N. |
|
| November 17, 2016 |
Unassociated Document J.P. Morgan J.P. Morgan AMENDMENT NO. 1, dated as of November , 2016 (the "Amendment"), to the Third Amended and Restated Deposit Agreement dated as of February 27, 2014 (the "Deposit Agreement") among Roche Holding Ltd (the "Company"), incorporated under the laws of Switzerland, JPMorgan Chase Bank, N.A., as depositary (the "Depositary"), and all holders from time to time of |
|
| November 17, 2016 |
F-6 POS 1 e615578f6pos-roche.htm As filed with the U.S. Securities and Exchange Commission on November 16, 2016 Registration No. 333-193846 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For American Depositary Shares Evidenced by American Depositary Receipts ROCHE HOLDING LTD (Exact name |
|
| November 17, 2016 |
Unassociated Document Certification under Rule 466 The depositary, JPMorgan Chase Bank, N. |
|
| March 17, 2016 |
POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents, that the undersigned hereby constitutes and appoints each of Darren K. |
|
| March 17, 2016 |
POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents, that the undersigned hereby constitutes and appoints each of Darren K. |
|
| March 17, 2016 |
POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents, that the undersigned hereby constitutes and appoints each of Darren K. |
|
| March 17, 2016 |
POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents, that the undersigned hereby constitutes and appoints each of Darren K. |
|
| April 23, 2015 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundation Medicine, Inc. and (ii) that this Joi |
|
| April 23, 2015 |
FMI / Foundation Medicine, Inc. / ROCHE HOLDING LTD - SC 13D/A Activist Investment SC 13D/A 1 dp55370sc13da-2.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 Foundation Medicine, Inc. (Name of Issuer) Common Stock, 0.0001 par value per share (Title of Class of Securities) 350456100 (CUSIP Number) Beat Kraehenmann Roche Holding Ltd Grenzacherstrasse 124 CH-4070 Basel, S |
|
| April 9, 2015 |
EX-99.2 2 dp55183ex9902.htm EXHIBIT 99.2 Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundat |
|
| April 9, 2015 |
EX-99.2 2 dp55183ex9902.htm EXHIBIT 99.2 Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundat |
|
| April 9, 2015 |
EX-99.2 2 dp55183ex9902.htm EXHIBIT 99.2 Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundat |
|
| April 9, 2015 |
EX-99.2 2 dp55183ex9902.htm EXHIBIT 99.2 Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundat |
|
| April 9, 2015 |
FMI / Foundation Medicine, Inc. / ROCHE HOLDING LTD - SCHEDULE 13D/A Activist Investment SC 13D/A 1 dp55183sc13da-a1.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Foundation Medicine, Inc. (Name of Issuer) Common Stock, 0.0001 par value per share (Title of Class of Securities) 350456100 (CUSIP Number) Beat Kraehenmann Roche Holding Ltd Grenzacherstrasse 124 CH-4070 B |
|
| January 21, 2015 |
Exhibit 99.2 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entity listed on Schedule A hereto (the “VC Shareholder”). WHEREAS, as of the date hereof, the VC Shareholder is the beneficial owner (as defined in Rule 13d-3 promulgated under the Excha |
|
| January 21, 2015 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundation Medicine, Inc. and (ii) that this Joi |
|
| January 21, 2015 |
Exhibit 99.2 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entity listed on Schedule A hereto (the “VC Shareholder”). WHEREAS, as of the date hereof, the VC Shareholder is the beneficial owner (as defined in Rule 13d-3 promulgated under the Excha |
|
| January 21, 2015 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundation Medicine, Inc. and (ii) that this Joi |
|
| January 21, 2015 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundation Medicine, Inc. and (ii) that this Joi |
|
| January 21, 2015 |
Exhibit 99.3 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entities listed on Schedule A hereto (the “VC Shareholders” and each a “VC Shareholder”). WHEREAS, as of the date hereof, each VC Shareholder is the beneficial owner (as defined in Rule 1 |
|
| January 21, 2015 |
Exhibit 99.3 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entities listed on Schedule A hereto (the “VC Shareholders” and each a “VC Shareholder”). WHEREAS, as of the date hereof, each VC Shareholder is the beneficial owner (as defined in Rule 1 |
|
| January 21, 2015 |
Exhibit 99.4 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entity listed on Schedule A hereto (the “VC Shareholder”). WHEREAS, as of the date hereof, the VC Shareholder is the beneficial owner (as defined in Rule 13d-3 promulgated under the Excha |
|
| January 21, 2015 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundation Medicine, Inc. and (ii) that this Joi |
|
| January 21, 2015 |
FMI / Foundation Medicine, Inc. / ROCHE HOLDING LTD - FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Foundation Medicine, Inc. (Name of Issuer) Common Stock, 0.0001 par value per share (Title of Class of Securities) 350456100 (CUSIP Number) Beat Kraehenmann Roche Holding Ltd Grenzacherstrasse 124 CH-4070 Basel, Switzerland Telephone: +41-61-688-1111 (Name, Address and Tel |
|
| January 21, 2015 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundation Medicine, Inc. and (ii) that this Joi |
|
| January 21, 2015 |
Exhibit 99.3 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entities listed on Schedule A hereto (the “VC Shareholders” and each a “VC Shareholder”). WHEREAS, as of the date hereof, each VC Shareholder is the beneficial owner (as defined in Rule 1 |
|
| January 21, 2015 |
Exhibit 99.4 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entity listed on Schedule A hereto (the “VC Shareholder”). WHEREAS, as of the date hereof, the VC Shareholder is the beneficial owner (as defined in Rule 13d-3 promulgated under the Excha |
|
| January 21, 2015 |
Exhibit 99.2 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entity listed on Schedule A hereto (the “VC Shareholder”). WHEREAS, as of the date hereof, the VC Shareholder is the beneficial owner (as defined in Rule 13d-3 promulgated under the Excha |
|
| January 21, 2015 |
Exhibit 99.3 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entities listed on Schedule A hereto (the “VC Shareholders” and each a “VC Shareholder”). WHEREAS, as of the date hereof, each VC Shareholder is the beneficial owner (as defined in Rule 1 |
|
| January 21, 2015 |
Exhibit 99.2 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entity listed on Schedule A hereto (the “VC Shareholder”). WHEREAS, as of the date hereof, the VC Shareholder is the beneficial owner (as defined in Rule 13d-3 promulgated under the Excha |
|
| January 21, 2015 |
Exhibit 99.4 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entity listed on Schedule A hereto (the “VC Shareholder”). WHEREAS, as of the date hereof, the VC Shareholder is the beneficial owner (as defined in Rule 13d-3 promulgated under the Excha |
|
| January 21, 2015 |
Exhibit 99.3 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entities listed on Schedule A hereto (the “VC Shareholders” and each a “VC Shareholder”). WHEREAS, as of the date hereof, each VC Shareholder is the beneficial owner (as defined in Rule 1 |
|
| January 21, 2015 |
Exhibit 99.4 EXECUTION TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”) dated as of January 11, 2015 by and among Roche Holdings, Inc., a Delaware corporation (the “Investor”), and the entity listed on Schedule A hereto (the “VC Shareholder”). WHEREAS, as of the date hereof, the VC Shareholder is the beneficial owner (as defined in Rule 13d-3 promulgated under the Excha |
|
| January 12, 2015 |
Roche/Foundation Medicine collaboration: - Advancing patient care and science in oncology IR conference call, 12 January 2015 1 CAUTIONARY STATEMENT REGARDING FORWARD -LOOKING STATEMENTS SOME OF THE STATEMENTS CONTAINED IN THESE MATERIALS ARE FORWARD -LOOKING STATEMENTS, INCLUDING STATEMENTS REGARDING THE EXPECTED CONSUMMATION OF THE TRANSACTION, WHICH INVOLVES A NUMBER OF RISKS AND UNCERTAINTIES, |
|
| January 12, 2015 |
Media Release Basel, 12 January 2015 Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer • Roche to acquire a majority interest in Foundation Medicine (FMI) of up to 56. |
|
| January 12, 2015 |
Roche/Foundation Medicine collaboration: - Advancing patient care and science in oncology IR conference call, 12 January 2015 1 CAUTIONARY STATEMENT REGARDING FORWARD -LOOKING STATEMENTS SOME OF THE STATEMENTS CONTAINED IN THESE MATERIALS ARE FORWARD -LOOKING STATEMENTS, INCLUDING STATEMENTS REGARDING THE EXPECTED CONSUMMATION OF THE TRANSACTION, WHICH INVOLVES A NUMBER OF RISKS AND UNCERTAINTIES, |
|
| January 12, 2015 |
Media Release Basel, 12 January 2015 Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer • Roche to acquire a majority interest in Foundation Medicine (FMI) of up to 56. |
|
| January 12, 2015 |
Media Release Basel, 12 January 2015 Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer • Roche to acquire a majority interest in Foundation Medicine (FMI) of up to 56. |
|
| January 12, 2015 |
RHHBF / Roche Holding Ltd SC TO-C - - FORM SC TO-C SC TO-C 1 dp52529sctoc.htm FORM SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 FOUNDATION MEDICINE, INC. (Name of Subject Company) ROCHE HOLDINGS, INC. (Names of Filing Persons - Offeror) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securitie |
|
| January 12, 2015 |
Media Release Basel, 12 January 2015 Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer • Roche to acquire a majority interest in Foundation Medicine (FMI) of up to 56. |
|
| January 12, 2015 |
Media Release Basel, 12 January 2015 Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer • Roche to acquire a majority interest in Foundation Medicine (FMI) of up to 56. |
|
| January 12, 2015 |
Roche/Foundation Medicine collaboration: - Advancing patient care and science in oncology IR conference call, 12 January 2015 1 CAUTIONARY STATEMENT REGARDING FORWARD -LOOKING STATEMENTS SOME OF THE STATEMENTS CONTAINED IN THESE MATERIALS ARE FORWARD -LOOKING STATEMENTS, INCLUDING STATEMENTS REGARDING THE EXPECTED CONSUMMATION OF THE TRANSACTION, WHICH INVOLVES A NUMBER OF RISKS AND UNCERTAINTIES, |
|
| January 12, 2015 |
Key Messages and Q&A: Project Hermes Key Messages and Q&A: Project Hermes 12 January, 2015 Approved spokespeople: Nicolas Dunant, Ulrike Engels-Lange, Stepan Kracala, Ed Lang, Karl Mahler, Tamer Farhan The messages and Q&A below are to be used in response to media and investor enquiries. |
|
| January 12, 2015 |
Roche/Foundation Medicine collaboration: - Advancing patient care and science in oncology IR conference call, 12 January 2015 1 CAUTIONARY STATEMENT REGARDING FORWARD -LOOKING STATEMENTS SOME OF THE STATEMENTS CONTAINED IN THESE MATERIALS ARE FORWARD -LOOKING STATEMENTS, INCLUDING STATEMENTS REGARDING THE EXPECTED CONSUMMATION OF THE TRANSACTION, WHICH INVOLVES A NUMBER OF RISKS AND UNCERTAINTIES, |
|
| January 12, 2015 |
Roche/Foundation Medicine collaboration: - Advancing patient care and science in oncology IR conference call, 12 January 2015 1 CAUTIONARY STATEMENT REGARDING FORWARD -LOOKING STATEMENTS SOME OF THE STATEMENTS CONTAINED IN THESE MATERIALS ARE FORWARD -LOOKING STATEMENTS, INCLUDING STATEMENTS REGARDING THE EXPECTED CONSUMMATION OF THE TRANSACTION, WHICH INVOLVES A NUMBER OF RISKS AND UNCERTAINTIES, |
|
| February 10, 2014 |
F-6EF 1 e611804f6ef-roche.htm As filed with the U.S. Securities and Exchange Commission on February 10, 2014 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For American Depositary Shares Evidenced by American Depositary Receipts ROCHE HOLDING LTD (Exact name of issuer of deposited securities as specif |
|
| February 10, 2014 |
Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 February 10, 2014 JPMorgan Chase Bank, N. |
|
| February 10, 2014 |
Certification under Rule 466 The depositary, JPMorgan Chase Bank, N.A. represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (Roche Holding Ltd, 333-156008) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement. (2) That its ability to designate the date and time of effe |
|
| February 10, 2014 |
Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 February 10, 2014 JPMorgan Chase Bank, N. |
|
| February 10, 2014 |
Certification under Rule 466 The depositary, JPMorgan Chase Bank, N.A. represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (Roche Holding Ltd, 333-156008) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement. (2) That its ability to designate the date and time of effe |
|
| February 10, 2014 |
J.P.Morgan J.P.Morgan TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Custodian 1 (e) Deliver, execute, issue et al. 1 (f) Delivery Order 1 (g) Deposited Securities 2 (h) Direct Registration System 2 (i) Holder 2 (j) Securities Act of 1933 2 (k) Securities Exchange Act of 1934 2 (l) Shares 2 (m) Transf |
|
| February 10, 2014 |
Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 February 10, 2014 JPMorgan Chase Bank, N. |
|
| February 10, 2014 |
J.P.Morgan J.P.Morgan TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Custodian 1 (e) Deliver, execute, issue et al. 1 (f) Delivery Order 1 (g) Deposited Securities 2 (h) Direct Registration System 2 (i) Holder 2 (j) Securities Act of 1933 2 (k) Securities Exchange Act of 1934 2 (l) Shares 2 (m) Transf |
|
| February 10, 2014 |
Certification under Rule 466 The depositary, JPMorgan Chase Bank, N.A. represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (Roche Holding Ltd, 333-156008) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement. (2) That its ability to designate the date and time of effe |
|
| February 10, 2014 |
Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 February 10, 2014 JPMorgan Chase Bank, N. |
|
| February 10, 2014 |
J.P.Morgan J.P.Morgan TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Custodian 1 (e) Deliver, execute, issue et al. 1 (f) Delivery Order 1 (g) Deposited Securities 2 (h) Direct Registration System 2 (i) Holder 2 (j) Securities Act of 1933 2 (k) Securities Exchange Act of 1934 2 (l) Shares 2 (m) Transf |
|
| February 10, 2014 |
J.P.Morgan J.P.Morgan TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Custodian 1 (e) Deliver, execute, issue et al. 1 (f) Delivery Order 1 (g) Deposited Securities 2 (h) Direct Registration System 2 (i) Holder 2 (j) Securities Act of 1933 2 (k) Securities Exchange Act of 1934 2 (l) Shares 2 (m) Transf |
|
| February 10, 2014 |
Certification under Rule 466 The depositary, JPMorgan Chase Bank, N.A. represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (Roche Holding Ltd, 333-156008) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement. (2) That its ability to designate the date and time of effe |
|
| February 10, 2014 |
J.P.Morgan J.P.Morgan TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Custodian 1 (e) Deliver, execute, issue et al. 1 (f) Delivery Order 1 (g) Deposited Securities 2 (h) Direct Registration System 2 (i) Holder 2 (j) Securities Act of 1933 2 (k) Securities Exchange Act of 1934 2 (l) Shares 2 (m) Transf |
|
| February 10, 2014 |
Certification under Rule 466 The depositary, JPMorgan Chase Bank, N.A. represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (Roche Holding Ltd, 333-156008) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement. (2) That its ability to designate the date and time of effe |
|
| February 10, 2014 |
Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 February 10, 2014 JPMorgan Chase Bank, N. |
|
| January 15, 2013 |
ARWR / Arrowhead Pharmaceuticals, Inc. / ROCHE HOLDING LTD - SC 13G/A1 Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(b) Arrowhead Research Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 042797 10 0 (CUSIP Number) December 31, 2012 (Date of Event |
|
| April 12, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| April 11, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| April 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| April 4, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| April 3, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 30, 2012 |
DFAN14A 1 dp29631dfan14a-roche.htm FORM DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Prelim |
|
| March 29, 2012 |
DFAN14A 1 dp29594defan14a.htm FORM DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary |
|
| March 26, 2012 |
DFAN14A 1 dp29502dfan14a.htm DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy |
|
| March 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 19, 2012 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant ý Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to Section 240. |
|
| March 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 7, 2012 |
New York Menlo Park Washington DC São Paulo London Paris Madrid Tokyo Beijing Hong Kong Marc O. |
|
| March 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 2, 2012 |
PRRN14A 1 a2207784zprrn14a.htm PRRN14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant o Filed by a Party other than the Registrant ý Check the |
|
| March 2, 2012 |
New York Menlo Park Washington DC São Paulo London Paris Madrid Tokyo Beijing Hong Kong Marc O. |
|
| February 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| February 22, 2012 |
CORRESP 1 filename1.htm New York Menlo Park Washington DC São Paulo London Paris Madrid Tokyo Beijing Hong Kong Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 212 450 6145 tel 212 701 5843 fax February 22, 2012 Re: Illumina, Inc. Amendment No. 8 to Schedule TO filed on February 16, 2012 Filed by CKH Acquisition Corporation and Roche Holding Ltd File No. 5-60457 Peggy Kim Securit |
|
| February 16, 2012 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| February 15, 2012 |
New York Menlo Park Washington DC São Paulo London Paris Madrid Tokyo Beijing Hong Kong Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 212 450 6145 tel 212 701 5843 fax February 15, 2012 Re: Illumina, Inc. |
|
| February 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| February 8, 2012 |
DFAN14A 1 dp28636dfan14a.htm FORM DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary |
|
| February 8, 2012 |
DFAN14A 1 dp28634dfan14a.htm FORM DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary |
|
| February 8, 2012 |
New York Menlo Park Washington DC São Paulo London Paris Madrid Tokyo Beijing Hong Kong Marc O. |
|
| February 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| February 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| February 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| February 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 31, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 31, 2012 |
DFAN14A 1 dp28387dfan14a.htm FORM DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary |
|
| January 31, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| October 28, 2011 |
SC 13G 1 dp26962sc13g.htm FORM SC13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(b) Arrowhead Research Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 042797 10 0 (CUSIP Number) October 21, 20 |
|
| December 9, 2008 |
Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 December 8, 2008 JPMorgan Chase Bank, N. |
|
| December 9, 2008 |
Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 December 8, 2008 JPMorgan Chase Bank, N. |
|
| December 9, 2008 |
ROCHE HOLDING LTD AND JPMORGAN CHASE BANK, N.A., As Depositary AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS Second Amended and Restated Deposit Agreement Dated as of December 19, 2008 TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 2 (d) Custodian 2 (e) Deliver, execute, issue et al. 2 (f) Delivery Order 2 (g |
|
| December 9, 2008 |
ROCHE HOLDING LTD AND JPMORGAN CHASE BANK, N.A., As Depositary AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS Second Amended and Restated Deposit Agreement Dated as of December 19, 2008 TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 2 (d) Custodian 2 (e) Deliver, execute, issue et al. 2 (f) Delivery Order 2 (g |
|
| December 9, 2008 |
ROCHE HOLDING LTD AND JPMORGAN CHASE BANK, N.A., As Depositary AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS Second Amended and Restated Deposit Agreement Dated as of December 19, 2008 TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 2 (d) Custodian 2 (e) Deliver, execute, issue et al. 2 (f) Delivery Order 2 (g |
|
| December 9, 2008 |
Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 December 8, 2008 JPMorgan Chase Bank, N. |
|
| December 9, 2008 |
ROCHE HOLDING LTD AND JPMORGAN CHASE BANK, N.A., As Depositary AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS Second Amended and Restated Deposit Agreement Dated as of December 19, 2008 TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 2 (d) Custodian 2 (e) Deliver, execute, issue et al. 2 (f) Delivery Order 2 (g |
|
| December 9, 2008 |
ROCHE HOLDING LTD AND JPMORGAN CHASE BANK, N.A., As Depositary AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS Second Amended and Restated Deposit Agreement Dated as of December 19, 2008 TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 2 (d) Custodian 2 (e) Deliver, execute, issue et al. 2 (f) Delivery Order 2 (g |
|
| December 9, 2008 |
As filed with the U.S. Securities and Exchange Commission on December 8, 2008 F-6 1 v134339f-6.htm As filed with the U.S. Securities and Exchange Commission on December 8, 2008 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For American Depositary Shares Evidenced by American Depositary Receipts ROCHE HOLDING LTD (Exact name of issuer of deposited securities as specified in its |
|
| December 9, 2008 |
Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 December 8, 2008 JPMorgan Chase Bank, N. |
|
| February 19, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 22 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons ? Offeror) Common Stock, Par Value $0.001 Per Share (i |
|
| February 19, 2008 |
Exhibit (a)(5)(xxi) Media Release Basel, Switzerland, February 19, 2008 Roche Completes Tender Offer for Ventana Shares Acquisition of Ventana to be Completed Today Roche (SWX: ROG. |
|
| February 19, 2008 |
Exhibit (a)(5)(xxi) Media Release Basel, Switzerland, February 19, 2008 Roche Completes Tender Offer for Ventana Shares Acquisition of Ventana to be Completed Today Roche (SWX: ROG. |
|
| February 19, 2008 |
Exhibit (a)(5)(xxi) Media Release Basel, Switzerland, February 19, 2008 Roche Completes Tender Offer for Ventana Shares Acquisition of Ventana to be Completed Today Roche (SWX: ROG. |
|
| February 19, 2008 |
Exhibit (a)(5)(xxi) Media Release Basel, Switzerland, February 19, 2008 Roche Completes Tender Offer for Ventana Shares Acquisition of Ventana to be Completed Today Roche (SWX: ROG. |
|
| February 19, 2008 |
Exhibit (a)(5)(xxi) Media Release Basel, Switzerland, February 19, 2008 Roche Completes Tender Offer for Ventana Shares Acquisition of Ventana to be Completed Today Roche (SWX: ROG. |
|
| February 8, 2008 |
Media Release Basel, Switzerland, February 8, 2008 Roche Purchases Shares in Tender Offer For Ventana Commences Subsequent Offering Period Roche (SWX: ROG. |
|
| February 8, 2008 |
Media Release Basel, Switzerland, February 8, 2008 Roche Purchases Shares in Tender Offer For Ventana Commences Subsequent Offering Period Roche (SWX: ROG. |
|
| February 8, 2008 |
Media Release Basel, Switzerland, February 8, 2008 Roche Purchases Shares in Tender Offer For Ventana Commences Subsequent Offering Period Roche (SWX: ROG. |
|
| February 8, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 21 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons ? Offeror) Common Stock, Par Value $0.001 Per Share (i |
|
| February 1, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION SC TO-T/A 1 dp08473sctota20.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 20 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons — Offeror) Common Stoc |
|
| January 31, 2008 |
Media Release Basel, Switzerland, January 31, 2008 Roche Plans To Complete Ventana Offer on February 7th Roche (SWX: ROG. |
|
| January 31, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 19 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons ? Offeror) Common Stock, Par Value $0.001 Per Share (i |
|
| January 31, 2008 |
Media Release Basel, Switzerland, January 31, 2008 Roche Plans To Complete Ventana Offer on February 7th Roche (SWX: ROG. |
|
| January 31, 2008 |
Media Release Basel, Switzerland, January 31, 2008 Roche Plans To Complete Ventana Offer on February 7th Roche (SWX: ROG. |
|
| January 31, 2008 |
Media Release Basel, Switzerland, January 31, 2008 Roche Plans To Complete Ventana Offer on February 7th Roche (SWX: ROG. |
|
| January 31, 2008 |
Media Release Basel, Switzerland, January 31, 2008 Roche Plans To Complete Ventana Offer on February 7th Roche (SWX: ROG. |
|
| January 25, 2008 |
EX-99.A.1.X 4 y47153exv99waw1wx.htm EX-99.A.1.X Exhibit (a)(1)(x) AMENDED AND RESTATED NOTICE OF GUARANTEED DELIVERY To Tender Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. Pursuant to the Amended and Restated Offer to Purchase dated January 25, 2008 by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche H |
|
| January 25, 2008 |
EX-99.A.1.XI 5 y47153exv99waw1wxi.htm EX-99.A.1.XI Exhibit (a)(1)(xi) Amended and Restated Offer to Purchase for Cash All Outstanding Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. at $89.50 Net Per Share by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche Holding Ltd THE OFFER AND WITHDRAWAL RIGHTS EXPI |
|
| January 25, 2008 |
Exhibit (a)(1)(ix) AMENDED AND RESTATED LETTER OF TRANSMITTAL To Tender Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. |
|
| January 25, 2008 |
EX-99.A.1.VIII 2 y47153exv99waw1wviii.htm EX-99.A.1.VIII Table of Contents Exhibit (a)(1)(viii) Amended and Restated Offer to Purchase for Cash All Outstanding Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. at $89.50 Net Per Share by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche Holding Ltd THE OFFER |
|
| January 25, 2008 |
Exhibit (a)(1)(xii) Amended and Restated Offer to Purchase for Cash All Outstanding Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. |
|
| January 25, 2008 |
EX-99.A.1.VIII 2 y47153exv99waw1wviii.htm EX-99.A.1.VIII Table of Contents Exhibit (a)(1)(viii) Amended and Restated Offer to Purchase for Cash All Outstanding Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. at $89.50 Net Per Share by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche Holding Ltd THE OFFER |
|
| January 25, 2008 |
EX-99.A.1.VIII 2 y47153exv99waw1wviii.htm EX-99.A.1.VIII Table of Contents Exhibit (a)(1)(viii) Amended and Restated Offer to Purchase for Cash All Outstanding Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. at $89.50 Net Per Share by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche Holding Ltd THE OFFER |
|
| January 25, 2008 |
EX-99.A.1.XI 5 y47153exv99waw1wxi.htm EX-99.A.1.XI Exhibit (a)(1)(xi) Amended and Restated Offer to Purchase for Cash All Outstanding Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. at $89.50 Net Per Share by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche Holding Ltd THE OFFER AND WITHDRAWAL RIGHTS EXPI |
|
| January 25, 2008 |
EX-99.A.1.XI 5 y47153exv99waw1wxi.htm EX-99.A.1.XI Exhibit (a)(1)(xi) Amended and Restated Offer to Purchase for Cash All Outstanding Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. at $89.50 Net Per Share by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche Holding Ltd THE OFFER AND WITHDRAWAL RIGHTS EXPI |
|
| January 25, 2008 |
SC TO-T/A 1 y47153sctovtza.htm AMENDMENT NO. 18 TO SCHEDULE TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 18 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Fili |
|
| January 25, 2008 |
Exhibit (a)(1)(ix) AMENDED AND RESTATED LETTER OF TRANSMITTAL To Tender Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. |
|
| January 25, 2008 |
Exhibit (a)(1)(ix) AMENDED AND RESTATED LETTER OF TRANSMITTAL To Tender Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. |
|
| January 25, 2008 |
EX-99.A.1.X 4 y47153exv99waw1wx.htm EX-99.A.1.X Exhibit (a)(1)(x) AMENDED AND RESTATED NOTICE OF GUARANTEED DELIVERY To Tender Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. Pursuant to the Amended and Restated Offer to Purchase dated January 25, 2008 by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche H |
|
| January 25, 2008 |
EX-99.A.1.VIII 2 y47153exv99waw1wviii.htm EX-99.A.1.VIII Table of Contents Exhibit (a)(1)(viii) Amended and Restated Offer to Purchase for Cash All Outstanding Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. at $89.50 Net Per Share by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche Holding Ltd THE OFFER |
|
| January 25, 2008 |
EX-99.A.1.X 4 y47153exv99waw1wx.htm EX-99.A.1.X Exhibit (a)(1)(x) AMENDED AND RESTATED NOTICE OF GUARANTEED DELIVERY To Tender Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. Pursuant to the Amended and Restated Offer to Purchase dated January 25, 2008 by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche H |
|
| January 25, 2008 |
Exhibit (a)(1)(xii) Amended and Restated Offer to Purchase for Cash All Outstanding Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. |
|
| January 25, 2008 |
Exhibit (a)(1)(ix) AMENDED AND RESTATED LETTER OF TRANSMITTAL To Tender Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. |
|
| January 25, 2008 |
EX-99.A.1.X 4 y47153exv99waw1wx.htm EX-99.A.1.X Exhibit (a)(1)(x) AMENDED AND RESTATED NOTICE OF GUARANTEED DELIVERY To Tender Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. Pursuant to the Amended and Restated Offer to Purchase dated January 25, 2008 by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche H |
|
| January 25, 2008 |
Exhibit (a)(1)(ix) AMENDED AND RESTATED LETTER OF TRANSMITTAL To Tender Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. |
|
| January 25, 2008 |
Exhibit (a)(1)(xii) Amended and Restated Offer to Purchase for Cash All Outstanding Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. |
|
| January 25, 2008 |
Exhibit (a)(1)(xii) Amended and Restated Offer to Purchase for Cash All Outstanding Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. |
|
| January 25, 2008 |
EX-99.A.1.X 4 y47153exv99waw1wx.htm EX-99.A.1.X Exhibit (a)(1)(x) AMENDED AND RESTATED NOTICE OF GUARANTEED DELIVERY To Tender Shares of Common Stock (including any associated preferred stock purchase rights) of Ventana Medical Systems, Inc. Pursuant to the Amended and Restated Offer to Purchase dated January 25, 2008 by Rocket Acquisition Corporation an indirect wholly owned subsidiary of Roche H |
|
| January 22, 2008 |
EX-99.A5(XVII) 2 dp08279ex-a5xvii.htm Exhibit (a)(5)(xvii) Media Release For Immediate Release Basel, Switzerland and Tucson, AZ, January 22, 2008 Roche to Acquire Ventana for $89.50 per share Roche and Ventana Reach Definitive Merger Agreement Roche (SWX: ROG.VX; RO.S; OTCQX: RHHBY), a world-leading healthcare provider of pharmaceuticals and diagnostics, and Ventana Medical Systems (“Ventana”) (N |
|
| January 22, 2008 |
EX-99.D2 8 dp08279ex99d2.htm Exhibit (d)(2) GUARANTEE GUARANTEE dated as of January 21, 2008 by Roche Holding Ltd, a joint stock company organized under the laws of Switzerland (the “Guarantor”), for the benefit of Ventana Medical Systems, Inc. (the “Beneficiary”). W I T N E S S E T H : WHEREAS, Roche Holdings, Inc., a Delaware corporation (the “Obligor”) is an indirect wholly-owned subsidiary of |
|
| January 22, 2008 |
EX-99.A5(XVII) 2 dp08279ex-a5xvii.htm Exhibit (a)(5)(xvii) Media Release For Immediate Release Basel, Switzerland and Tucson, AZ, January 22, 2008 Roche to Acquire Ventana for $89.50 per share Roche and Ventana Reach Definitive Merger Agreement Roche (SWX: ROG.VX; RO.S; OTCQX: RHHBY), a world-leading healthcare provider of pharmaceuticals and diagnostics, and Ventana Medical Systems (“Ventana”) (N |
|
| January 22, 2008 |
EX-99.A5(XVII) 2 dp08279ex-a5xvii.htm Exhibit (a)(5)(xvii) Media Release For Immediate Release Basel, Switzerland and Tucson, AZ, January 22, 2008 Roche to Acquire Ventana for $89.50 per share Roche and Ventana Reach Definitive Merger Agreement Roche (SWX: ROG.VX; RO.S; OTCQX: RHHBY), a world-leading healthcare provider of pharmaceuticals and diagnostics, and Ventana Medical Systems (“Ventana”) (N |
|
| January 22, 2008 |
Exhibit (d)(1) AGREEMENT AND PLAN OF MERGER dated as of January 21, 2008 among VENTANA MEDICAL SYSTEMS, INC. |
|
| January 22, 2008 |
Exhibit (d)(1) AGREEMENT AND PLAN OF MERGER dated as of January 21, 2008 among VENTANA MEDICAL SYSTEMS, INC. |
|
| January 22, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION SC TO-T/A 1 dp08279sctota17.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 17 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons — Offeror) Common Stoc |
|
| January 22, 2008 |
EX-99.D2 8 dp08279ex99d2.htm Exhibit (d)(2) GUARANTEE GUARANTEE dated as of January 21, 2008 by Roche Holding Ltd, a joint stock company organized under the laws of Switzerland (the “Guarantor”), for the benefit of Ventana Medical Systems, Inc. (the “Beneficiary”). W I T N E S S E T H : WHEREAS, Roche Holdings, Inc., a Delaware corporation (the “Obligor”) is an indirect wholly-owned subsidiary of |
|
| January 22, 2008 |
STOCKHOLDER TENDER AND SUPPORT AGREEMENT EX-99.D3 9 dp08279ex99d3.htm Exhibit (d)(3) STOCKHOLDER TENDER AND SUPPORT AGREEMENT This Stockholder Tender and Support Agreement dated as of January 21, 2008 (this “Agreement”) is among each of the individuals or entities listed on a signature page hereto (each, a “Stockholder”) and Roche Holdings, Inc., a Delaware corporation (“Parent”). Capitalized terms used but not defined herein have the me |
|
| January 22, 2008 |
Exhibit (d)(1) AGREEMENT AND PLAN OF MERGER dated as of January 21, 2008 among VENTANA MEDICAL SYSTEMS, INC. |
|
| January 22, 2008 |
EX-99.D2 8 dp08279ex99d2.htm Exhibit (d)(2) GUARANTEE GUARANTEE dated as of January 21, 2008 by Roche Holding Ltd, a joint stock company organized under the laws of Switzerland (the “Guarantor”), for the benefit of Ventana Medical Systems, Inc. (the “Beneficiary”). W I T N E S S E T H : WHEREAS, Roche Holdings, Inc., a Delaware corporation (the “Obligor”) is an indirect wholly-owned subsidiary of |
|
| January 22, 2008 |
EX-99.A5(XVIII) 3 dp08279ex-a5xviii.htm Exhibit (a)(5)(xviii) This announcement is not an offer to purchase or a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase dated June 27, 2007 and the related Letter of Transmittal, each as amended through January 22, 2008, and any amendments or supplements thereto and is being ma |
|
| January 22, 2008 |
EX-99.A5(XVII) 2 dp08279ex-a5xvii.htm Exhibit (a)(5)(xvii) Media Release For Immediate Release Basel, Switzerland and Tucson, AZ, January 22, 2008 Roche to Acquire Ventana for $89.50 per share Roche and Ventana Reach Definitive Merger Agreement Roche (SWX: ROG.VX; RO.S; OTCQX: RHHBY), a world-leading healthcare provider of pharmaceuticals and diagnostics, and Ventana Medical Systems (“Ventana”) (N |
|
| January 22, 2008 |
Exhibit (d)(1) AGREEMENT AND PLAN OF MERGER dated as of January 21, 2008 among VENTANA MEDICAL SYSTEMS, INC. |
|
| January 22, 2008 |
EX-99.D2 8 dp08279ex99d2.htm Exhibit (d)(2) GUARANTEE GUARANTEE dated as of January 21, 2008 by Roche Holding Ltd, a joint stock company organized under the laws of Switzerland (the “Guarantor”), for the benefit of Ventana Medical Systems, Inc. (the “Beneficiary”). W I T N E S S E T H : WHEREAS, Roche Holdings, Inc., a Delaware corporation (the “Obligor”) is an indirect wholly-owned subsidiary of |
|
| January 22, 2008 |
Exhibit (d)(1) AGREEMENT AND PLAN OF MERGER dated as of January 21, 2008 among VENTANA MEDICAL SYSTEMS, INC. |
|
| January 22, 2008 |
EX-99.A5(XVIII) 3 dp08279ex-a5xviii.htm Exhibit (a)(5)(xviii) This announcement is not an offer to purchase or a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase dated June 27, 2007 and the related Letter of Transmittal, each as amended through January 22, 2008, and any amendments or supplements thereto and is being ma |
|
| January 22, 2008 |
EX-99.D2 8 dp08279ex99d2.htm Exhibit (d)(2) GUARANTEE GUARANTEE dated as of January 21, 2008 by Roche Holding Ltd, a joint stock company organized under the laws of Switzerland (the “Guarantor”), for the benefit of Ventana Medical Systems, Inc. (the “Beneficiary”). W I T N E S S E T H : WHEREAS, Roche Holdings, Inc., a Delaware corporation (the “Obligor”) is an indirect wholly-owned subsidiary of |
|
| January 22, 2008 |
STOCKHOLDER TENDER AND SUPPORT AGREEMENT EX-99.D3 9 dp08279ex99d3.htm Exhibit (d)(3) STOCKHOLDER TENDER AND SUPPORT AGREEMENT This Stockholder Tender and Support Agreement dated as of January 21, 2008 (this “Agreement”) is among each of the individuals or entities listed on a signature page hereto (each, a “Stockholder”) and Roche Holdings, Inc., a Delaware corporation (“Parent”). Capitalized terms used but not defined herein have the me |
|
| January 22, 2008 |
STOCKHOLDER TENDER AND SUPPORT AGREEMENT EX-99.D3 9 dp08279ex99d3.htm Exhibit (d)(3) STOCKHOLDER TENDER AND SUPPORT AGREEMENT This Stockholder Tender and Support Agreement dated as of January 21, 2008 (this “Agreement”) is among each of the individuals or entities listed on a signature page hereto (each, a “Stockholder”) and Roche Holdings, Inc., a Delaware corporation (“Parent”). Capitalized terms used but not defined herein have the me |
|
| January 22, 2008 |
EX-99.A5(XVIII) 3 dp08279ex-a5xviii.htm Exhibit (a)(5)(xviii) This announcement is not an offer to purchase or a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase dated June 27, 2007 and the related Letter of Transmittal, each as amended through January 22, 2008, and any amendments or supplements thereto and is being ma |
|
| January 22, 2008 |
STOCKHOLDER TENDER AND SUPPORT AGREEMENT EX-99.D3 9 dp08279ex99d3.htm Exhibit (d)(3) STOCKHOLDER TENDER AND SUPPORT AGREEMENT This Stockholder Tender and Support Agreement dated as of January 21, 2008 (this “Agreement”) is among each of the individuals or entities listed on a signature page hereto (each, a “Stockholder”) and Roche Holdings, Inc., a Delaware corporation (“Parent”). Capitalized terms used but not defined herein have the me |
|
| January 16, 2008 |
Exhibit (a)(5)(xvi) Media Release Basel, January 16, 2008 Roche Extends Tender Offer for Ventana Roche (SWX: ROG. |
|
| January 16, 2008 |
DFAN14A 1 dp08247dfan14a.htm SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Ma |
|
| January 16, 2008 |
Exhibit (a)(5)(xvi) Media Release Basel, January 16, 2008 Roche Extends Tender Offer for Ventana Roche (SWX: ROG. |
|
| January 16, 2008 |
Exhibit (a)(5)(xvi) Media Release Basel, January 16, 2008 Roche Extends Tender Offer for Ventana Roche (SWX: ROG. |
|
| January 16, 2008 |
Exhibit (a)(5)(xvi) Media Release Basel, January 16, 2008 Roche Extends Tender Offer for Ventana Roche (SWX: ROG. |
|
| January 16, 2008 |
Exhibit (a)(5)(xvi) Media Release Basel, January 16, 2008 Roche Extends Tender Offer for Ventana Roche (SWX: ROG. |
|
| January 16, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 16 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons ? Offeror) Common Stock, Par Value $0.001 Per Share (i |
|
| December 5, 2007 |
EX-99.A.5.XV 2 dp07819exa5xv.htm Exhibit (a)(5)(xv) Media Release For Immediate Release Basel, November 13, 2007 Roche To Nominate Independent Directors for Election at Ventana’s 2008 Annual Stockholders Meeting Roche (SWX: ROG.VX; RO.S) announced today that it gave notice to Ventana Medical Systems, Inc. (Nasdaq: VMSI), as required by Ventana’s bylaws, that it will nominate independent candidates |
|
| December 5, 2007 |
EX-99.A.5.XV 2 dp07819exa5xv.htm Exhibit (a)(5)(xv) Media Release For Immediate Release Basel, November 13, 2007 Roche To Nominate Independent Directors for Election at Ventana’s 2008 Annual Stockholders Meeting Roche (SWX: ROG.VX; RO.S) announced today that it gave notice to Ventana Medical Systems, Inc. (Nasdaq: VMSI), as required by Ventana’s bylaws, that it will nominate independent candidates |
|
| December 5, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 15 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons ? Offeror) Common Stock, Par Value $0.001 Per Share (i |
|
| December 5, 2007 |
DFAN14A 1 dp07823dfan14a.htm SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Ma |
|
| December 5, 2007 |
EX-99.A.5.XV 2 dp07819exa5xv.htm Exhibit (a)(5)(xv) Media Release For Immediate Release Basel, November 13, 2007 Roche To Nominate Independent Directors for Election at Ventana’s 2008 Annual Stockholders Meeting Roche (SWX: ROG.VX; RO.S) announced today that it gave notice to Ventana Medical Systems, Inc. (Nasdaq: VMSI), as required by Ventana’s bylaws, that it will nominate independent candidates |
|
| December 5, 2007 |
EX-99.A.5.XV 2 dp07819exa5xv.htm Exhibit (a)(5)(xv) Media Release For Immediate Release Basel, November 13, 2007 Roche To Nominate Independent Directors for Election at Ventana’s 2008 Annual Stockholders Meeting Roche (SWX: ROG.VX; RO.S) announced today that it gave notice to Ventana Medical Systems, Inc. (Nasdaq: VMSI), as required by Ventana’s bylaws, that it will nominate independent candidates |
|
| November 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 14 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons ? Offeror) Common Stock, Par Value $0.001 Per Share (i |
|
| November 14, 2007 |
EX-99.A.5.XIV 2 dp07568exa5xiv.htm Exhibit (a)(5)(xiv) Media Release Basel, November 13, 2007 Roche Confirms Commencement of Due Diligence with Ventana Roche (SWX: ROG.VX; RO.S) confirmed today that it has entered into a confidentiality agreement with Ventana Medical Systems, Inc. (NASDAQ: VMSI) and that it will commence due diligence. Roche cautioned that there can be no assurance that an agreeme |
|
| November 14, 2007 |
EX-99.A.5.XIV 2 dp07568exa5xiv.htm Exhibit (a)(5)(xiv) Media Release Basel, November 13, 2007 Roche Confirms Commencement of Due Diligence with Ventana Roche (SWX: ROG.VX; RO.S) confirmed today that it has entered into a confidentiality agreement with Ventana Medical Systems, Inc. (NASDAQ: VMSI) and that it will commence due diligence. Roche cautioned that there can be no assurance that an agreeme |
|
| November 14, 2007 |
EX-99.A.5.XIV 2 dp07568exa5xiv.htm Exhibit (a)(5)(xiv) Media Release Basel, November 13, 2007 Roche Confirms Commencement of Due Diligence with Ventana Roche (SWX: ROG.VX; RO.S) confirmed today that it has entered into a confidentiality agreement with Ventana Medical Systems, Inc. (NASDAQ: VMSI) and that it will commence due diligence. Roche cautioned that there can be no assurance that an agreeme |
|
| November 14, 2007 |
EX-99.A.5.XIV 2 dp07568exa5xiv.htm Exhibit (a)(5)(xiv) Media Release Basel, November 13, 2007 Roche Confirms Commencement of Due Diligence with Ventana Roche (SWX: ROG.VX; RO.S) confirmed today that it has entered into a confidentiality agreement with Ventana Medical Systems, Inc. (NASDAQ: VMSI) and that it will commence due diligence. Roche cautioned that there can be no assurance that an agreeme |
|
| November 14, 2007 |
EX-99.A.5.XIV 2 dp07568exa5xiv.htm Exhibit (a)(5)(xiv) Media Release Basel, November 13, 2007 Roche Confirms Commencement of Due Diligence with Ventana Roche (SWX: ROG.VX; RO.S) confirmed today that it has entered into a confidentiality agreement with Ventana Medical Systems, Inc. (NASDAQ: VMSI) and that it will commence due diligence. Roche cautioned that there can be no assurance that an agreeme |
|
| October 30, 2007 |
EX-99.A.5.XII 2 dp07385exa5xii.htm Exhibit (a)(5)(xii) Media Release Basel, October 29, 2007 Roche Extends Tender Offer for Ventana Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (NASDAQ: VMSI) to 5:00 p.m., New York Cit |
|
| October 30, 2007 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY EX-99.A.5.XIII 3 dp07385exa5xiii.htm Exhibit (a)(5)(xiii) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY ROCHE HOLDINGS, INC., a Delaware Corporation; and ROCKET ACQUISITION CORPORATION, a Delaware Corporation, Plaintiffs, v. CHRISTOPHER M. GLEESON; JACK W. SCHULER; JOHN PATIENCE; THOMAS M. GROGAN; THOMAS D. BROWN; ROD DAMMEYER; EDWARD M. GILES; MARK C. MILLER; JAME |
|
| October 30, 2007 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY EX-99.A.5.XIII 3 dp07385exa5xiii.htm Exhibit (a)(5)(xiii) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY ROCHE HOLDINGS, INC., a Delaware Corporation; and ROCKET ACQUISITION CORPORATION, a Delaware Corporation, Plaintiffs, v. CHRISTOPHER M. GLEESON; JACK W. SCHULER; JOHN PATIENCE; THOMAS M. GROGAN; THOMAS D. BROWN; ROD DAMMEYER; EDWARD M. GILES; MARK C. MILLER; JAME |
|
| October 30, 2007 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY EX-99.A.5.XIII 3 dp07385exa5xiii.htm Exhibit (a)(5)(xiii) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY ROCHE HOLDINGS, INC., a Delaware Corporation; and ROCKET ACQUISITION CORPORATION, a Delaware Corporation, Plaintiffs, v. CHRISTOPHER M. GLEESON; JACK W. SCHULER; JOHN PATIENCE; THOMAS M. GROGAN; THOMAS D. BROWN; ROD DAMMEYER; EDWARD M. GILES; MARK C. MILLER; JAME |
|
| October 30, 2007 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY EX-99.A.5.XIII 3 dp07385exa5xiii.htm Exhibit (a)(5)(xiii) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY ROCHE HOLDINGS, INC., a Delaware Corporation; and ROCKET ACQUISITION CORPORATION, a Delaware Corporation, Plaintiffs, v. CHRISTOPHER M. GLEESON; JACK W. SCHULER; JOHN PATIENCE; THOMAS M. GROGAN; THOMAS D. BROWN; ROD DAMMEYER; EDWARD M. GILES; MARK C. MILLER; JAME |
|
| October 30, 2007 |
EX-99.A.5.XII 2 dp07385exa5xii.htm Exhibit (a)(5)(xii) Media Release Basel, October 29, 2007 Roche Extends Tender Offer for Ventana Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (NASDAQ: VMSI) to 5:00 p.m., New York Cit |
|
| October 30, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION SC TO-T/A 1 dp07385sctota13.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 13 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons — Offeror) Common Stoc |
|
| October 30, 2007 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY EX-99.A.5.XIII 3 dp07385exa5xiii.htm Exhibit (a)(5)(xiii) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY ROCHE HOLDINGS, INC., a Delaware Corporation; and ROCKET ACQUISITION CORPORATION, a Delaware Corporation, Plaintiffs, v. CHRISTOPHER M. GLEESON; JACK W. SCHULER; JOHN PATIENCE; THOMAS M. GROGAN; THOMAS D. BROWN; ROD DAMMEYER; EDWARD M. GILES; MARK C. MILLER; JAME |
|
| October 30, 2007 |
EX-99.A.5.XII 2 dp07385exa5xii.htm Exhibit (a)(5)(xii) Media Release Basel, October 29, 2007 Roche Extends Tender Offer for Ventana Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (NASDAQ: VMSI) to 5:00 p.m., New York Cit |
|
| September 21, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 12 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons — Offeror) Common Stock, Par Value $0.001 Per Share (i |
|
| September 20, 2007 |
SC TO-T/A 1 dp06950sctota11.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 11 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons — Offeror) Common Stoc |
|
| September 20, 2007 |
EX-99.A.5.XI 2 dp06950exa5xi.htm EXHIBIT (a)(5)(xi) Media Release Basel, September 19, 2007 Roche Extends Tender Offer for Ventana Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (NASDAQ: VMSI) to 5:00 p.m., New York City |
|
| September 20, 2007 |
EX-99.A.5.XI 2 dp06950exa5xi.htm EXHIBIT (a)(5)(xi) Media Release Basel, September 19, 2007 Roche Extends Tender Offer for Ventana Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (NASDAQ: VMSI) to 5:00 p.m., New York City |
|
| September 20, 2007 |
EX-99.A.5.XI 2 dp06950exa5xi.htm EXHIBIT (a)(5)(xi) Media Release Basel, September 19, 2007 Roche Extends Tender Offer for Ventana Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (NASDAQ: VMSI) to 5:00 p.m., New York City |
|
| September 20, 2007 |
EX-99.A.5.XI 2 dp06950exa5xi.htm EXHIBIT (a)(5)(xi) Media Release Basel, September 19, 2007 Roche Extends Tender Offer for Ventana Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (NASDAQ: VMSI) to 5:00 p.m., New York City |
|
| August 22, 2007 |
EX-99.A.5.X 2 dp06689ea5x.htm EXHIBIT (a)(5)(x) Media Release Basel, August 22, 2007 United States District Court for the District of Arizona Grants Roche's Motion for Preliminary Injunction Roche (SWX: ROG.VX; RO.S) announced that, on August 21, 2007, the United States District Court for the District of Arizona granted Roche's motion for a preliminary injunction enjoining Ventana Medical Systems |
|
| August 22, 2007 |
EX-99.A.5.IX 2 dp06683exa5ix.htm EXHIBIT (a)(5)(ix) Media Release Basel, August 21, 2007 Roche Extends Tender Offer for Ventana Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (NASDAQ: VMSI) to 5:00 p.m., New York City ti |
|
| August 22, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 10 to SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VENTANA MEDICAL SYSTEMS, INC. (Name of Subject Company) ROCKET ACQUISITION CORPORATION ROCHE HOLDING LTD (Names of Filing Persons — Offeror) Common Stock, Par Value $0.001 Per Share (i |
|
| August 22, 2007 |
EX-99.A.5.X 2 dp06689ea5x.htm EXHIBIT (a)(5)(x) Media Release Basel, August 22, 2007 United States District Court for the District of Arizona Grants Roche's Motion for Preliminary Injunction Roche (SWX: ROG.VX; RO.S) announced that, on August 21, 2007, the United States District Court for the District of Arizona granted Roche's motion for a preliminary injunction enjoining Ventana Medical Systems |
|
| August 22, 2007 |
EX-99.A.5.IX 2 dp06683exa5ix.htm EXHIBIT (a)(5)(ix) Media Release Basel, August 21, 2007 Roche Extends Tender Offer for Ventana Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (NASDAQ: VMSI) to 5:00 p.m., New York City ti |
|
| August 22, 2007 |
EX-99.A.5.IX 2 dp06683exa5ix.htm EXHIBIT (a)(5)(ix) Media Release Basel, August 21, 2007 Roche Extends Tender Offer for Ventana Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (NASDAQ: VMSI) to 5:00 p.m., New York City ti |
|
| August 22, 2007 |
EX-99.A.5.X 2 dp06689ea5x.htm EXHIBIT (a)(5)(x) Media Release Basel, August 22, 2007 United States District Court for the District of Arizona Grants Roche's Motion for Preliminary Injunction Roche (SWX: ROG.VX; RO.S) announced that, on August 21, 2007, the United States District Court for the District of Arizona granted Roche's motion for a preliminary injunction enjoining Ventana Medical Systems |
|
| August 22, 2007 |
EX-99.A.5.X 2 dp06689ea5x.htm EXHIBIT (a)(5)(x) Media Release Basel, August 22, 2007 United States District Court for the District of Arizona Grants Roche's Motion for Preliminary Injunction Roche (SWX: ROG.VX; RO.S) announced that, on August 21, 2007, the United States District Court for the District of Arizona granted Roche's motion for a preliminary injunction enjoining Ventana Medical Systems |
